Posted by 
By Amanda Gardner~HealthDay NewsA U.S. Food and Drug Administration advisory panel voted to recommend the expanded use of the vaccine for males 9 to 26. The FDA is not required to follow its advisory panels’ recommendations, but it typically does.
The vaccine targets the human papilloma virus, which can cause genital warts in both males and females, cervical cancer in women and also penile and anal cancer in men — although these remain much rarer than cervical malignancies.
The vaccine is manufactured by drug maker Merck & Co.
Merck had asked the FDA to approve Gardasil for males ages 9 to 26. It is already approved in females 9 and older to help prevent cervical cancer.
Before the Gardasil vote, the committee on Wednesday also voted that a second HPV vaccine, GlaxoSmithKline‘s Cervarix, seems safe for girls and women ages 10 to 25 for the prevention of cervical cancer. Studies have shown that the vaccine prevents infection with HPV 93 percent of the time. The introduction of Cervarix was delayed in 2007 when the FDA said it needed more research on the vaccine.
Related posts:
- U.S. Government Mandates HPV Vaccine for New U.S. Residents
- Two More Girls Die After Receiving Gardasil Cervical Cancer Vaccination
- Gardasil Researcher Drops A Bombshell
- The Great Human Papilloma Virus Vaccine Hoax Exposed
- CDC Takes Closer Look at Gardasil and Paralysis
- Two thousand schoolgirls suffer suspected ill-effects from cervical cancer vaccine
- Merck Dumps Vaccine Waste Into Water Supply
